Dupilumab Phase 4 Study

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Northwestern University
Study ID
NCT03411837
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
12 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dupilumab — BIOLOGICAL
    Biologic (monoclonal antibody)

Study Details

The investigators will monitor for the incidence of adverse-events in a prospective, longitudinal, non-interventional and observational real-world sub-study of adults patients with moderate-to-severe AD who are receiving dupilumab as standard-of-care therapy.

Key Dates

Start date
Oct 16, 2017
Status verified
Oct 2021
Primary completion
Aug 31, 2019
Completion
Aug 31, 2019

Study Design

Enrollment
46 participants (actual)

Arms

  • Arm: Dupilumab
    Patients with moderated-to-severe atopic dermatitis who are receiving dupilumab as a standard of care

Primary Outcome Measure

Quantified Itch Survey [ Time Frame: 1 to 3 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Northwestern University Department of DermatologyChicagoIllinois60611-

Find similar trials in Chicago, IL

By condition
Atopic dermatitis / eczema
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Northwestern University Department of Dermatology· Chicago, IL

Related Studies